Johns Manville Announces New CEO, Chairman Transition
17.6.2020 20:30:00 EEST | Business Wire | Press release
Johns Manville (JM), a global building and specialty products manufacturer and a Berkshire Hathaway company, announced today that Bob Wamboldt will become President and CEO on Sept. 1, 2020. Mary Rhinehart, the company’s current Chairman, President and CEO, will retain the role of Chairman.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200617005674/en/
Mary Rhinehart (Photo: Business Wire)
Wamboldt joined Johns Manville in 2003 and became President of JM’s Insulation Systems business in February 2017. He earlier led the Engineered Products North America and Roofing Systems businesses at JM. Wamboldt is also Chairman of the North American Insulation Manufacturers Association and previously served as president of the Asphalt Roofing Manufacturers Association.
“I have been privileged to lead each of our businesses and learn first-hand the strength of the Johns Manville customer relationships, products, technologies and people,” Wamboldt said. “I look forward to working with the JM team and our customers to make the company even stronger in the global markets we serve. I also want to thank Mary for her leadership and guidance over the years and know I will benefit from her continued support as Chairman.”
Before joining Johns Manville, Wamboldt worked 16 years at PPG Industries Inc., where he held a variety of positions in the company’s Fiber Glass and Coatings divisions. He earned a bachelor’s degree in chemistry from Lehigh University. He and his wife live in Denver.
Rhinehart became Johns Manville’s President and CEO in 2012 and assumed the additional role of Chairman in 2014. Before becoming President and CEO, she was the company’s Chief Financial Officer for eight years. During her more than 40 years with Johns Manville, she also held leadership roles in treasury, supply chain, M&A and human resources, and she managed several of the company’s business units.
“I am immensely proud of JM’s employees and all we have accomplished together,” Rhinehart said. “Johns Manville is an important part of my life, and its continued success is my top priority as we transition to new leadership. I am pleased to hand the company over to such an accomplished JM executive as Bob and am confident he and our 8,000 employees around the world will continue to build on JM’s 162-year track record of success.”
Johns Manville became a Berkshire Hathaway company in February 2001.
“Bob’s business acumen, broad base of experience, and extensive industry knowledge make him the natural successor to Mary as CEO,” said Greg Abel, Berkshire Hathaway’s Vice Chairman. “I also want to extend my gratitude to Mary for her dedication and commitment to JM over her entire career. Under her leadership as CEO, JM delivered exceptional performance, successfully expanded its market presence, and made sound, strategic investments to position the company for success well into the future.”
Warren Buffett, Chairman and CEO of Berkshire Hathaway, added: “Mary was everything we had hoped to find in a CEO.”
About Johns Manville
Johns Manville, a Berkshire Hathaway company (NYSE: BRK.A, BRK.B), is a leading manufacturer and marketer of premium-quality building and specialty products. In business since 1858, the Denver-based company has annual sales over $3 billion and holds leadership positions in all of the key markets that it serves. Johns Manville employs 8,000 people and operates 46 manufacturing facilities in North America, Europe and China. Additional information can be found at www.jm.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200617005674/en/
Contact information
Eric Brown, +1-303-809-2853
eric.brown@jm.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom